Clinical Studies Medical DevicesIn Vitro Diagnostics Pharmaceuticals
Search: cerca
 
Home
 
 

SESSIONE DI FORMAZIONE
per comprendere le differenze
tra la ISO 13485 ed
il QSR 21 CFR 820 della FDA

Roma, 11 maggio 2012

Info e iscrizione

print this page  

In Vitro Diagnostics EU/US Quality and Regulatory Services

Your partner from successful product launch to reaching your business objectives and beyond

US and European Device Regulatory
For over 20 years, a recognized resource for reliable and accurate US and European medical technologyregulatory expertise, including IVD instruments and reagents. Donawa Lifescience Consulting (DLC) also provides highly respected European Authorized Representative services.

Quality Systems

DLC is a recognized leader in US and European quality system development, implementation, assessment and compliance. Equally proficient with ISO 13485, 21 CFR 820 and PAL 169 quality systems.

 

Software Compliance

Compliance of medical device software with US and European regulatory requirements needs very specific expertise, which DLC has available to assist companies, from early development to market clearance.

 

Environmental Services

A new service for device companies, provided by our experienced Environmental Affairs Associate, helping companies meet the growing list of European environmental directives and standards.

 

Performance Evaluation Studies in Europe

Located throughout Europe, a full-service European CRO specializing in medical  and IVD devices and conducting clinical studies that are valid for the US and elsewhere. Visit our dedicated CRO website for further details.

 

The DLC Quality, Regulatory and IVD Study services are managed from our headquarters in the historical centre of Rome, Italy. Contact us either by e-mail for a confidential discussion about your project, or call Dr. Maria Donawa, President, on +39 06 578 2665.

New draft guidance on biosimilars from FDA. Click here.

Wilkinson to join MHRA as head of devices section. Click here.

EMA announces revised pharmaceutical legislation. Click here.

ECRI announces Top Ten Hazards for 2012. Click here.

Commission publishes several new guidance documents. Click here.

New draft guidance on biosimilars from FDA. Click here.

 

Copyright © 2006-2012  
Donawa Lifescience Consulting S.r.l. - All rights reserved. P.IVA/VAT N. IT10442731005